Investigational drug · Phase 3
VGA039
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Von Willebrand Diseases, Von Willebrand Disease (VWD).
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "VGA039"
First trial start
2023
Mar 16, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VGA039", any sponsor or status.
Conditions studied
As listed on its trial records.
- Von Willebrand Diseases
- Von Willebrand Disease (VWD)
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "VGA039" as an intervention, largest first.
- Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)Pivotal-lookingRecruiting
Vega Therapeutics, IncIndustry
NCT05776069 · 116 participants (planned) · Start Mar 16, 2023 · Primary completion Dec 2029
Drug: VGA039; VGA039 · For: Von Willebrand Diseases
Sites: Los Angeles, California; Sacramento, California; Aurora, Colorado · 25 sites in all
- Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)Pivotal-lookingRecruiting
Vega Therapeutics, IncIndustry
NCT07115004 · 60 participants (planned) · Start Oct 15, 2025 · Primary completion Oct 2028
Drug: VGA039 · For: Von Willebrand Disease (VWD)
Sites: Little Rock, Arkansas; Los Angeles, California; Palo Alto, California · 32 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Rebalancing agents in hemophilia: knowns, unknowns, and uncertainties.
Van Thillo Q, Hermans C · Haematologica 2025
- New and emerging therapies for women, girls, and people with the potential to menstruate with VWD.
Casari C, Leung J, James PD · Blood Adv 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.